Characterizing Lentiviral And Gammaretroviral Vectors By Batch DLS And FFF-MALS

By Austin Seal, Ashkaan Moinzadeh and Kazuhiro Oka, Baylor College of Medicine, Anatolii Purchel and Michelle Chen, Wyatt Technology Corp

Lentivirus and gammaretrovirus are the most popular retroviral vectors under development for novel gene and cell therapies, with more than 300 products in clinical trials as of 2021. The details revealed by FFF-MALS-DLS help scientists and process engineers understand lot-to-lot variations and critical manufacturing parameters, enabling production of these novel therapeutic products with consistently high quality.

Comprehensive and reliable characterization, along with accurate quantitation, are essential for ensuring the quality and efficacy of retrovirus-based vectors used in novel gene and cell therapies.

We were able to defeat the analytical challenges FFF-MALS-DLS by applying these key attributes: sample purity, sample size, degree of aggregation, stability, physical titer and more. Discover how both batch DLS and FFF-MALS-DLS measurements can be applied in every stage of the manufacturing process for screening, quantitation, extended characterization, process development and quality assurance.